Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...
High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...
This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...
In our mHealth focus month, Nicole May takes a look at the expanding mobile health market in the US and the opportunities in this area ... to Amgen MedInfo regarding an Amgen product and even ...
CNBC on MSN11d
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the marketThe FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
New York, USA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Myocardial Infarction Clinical Trial Pipeline Appears Robust With 45+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...
This year's report, powered by insights from the Clarivate Cortellis intelligence suite of products, highlights 11 therapies ...
Drug discovery is a key area for AI, given the speed at which models trained on massive datasets can tackle a variety of tasks. Last year, Nvidia said it was doubling down on AI-powered drug discovery ...
An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback